
After a string of years characterized by growth for Novo Nordisk, in 2022, the Danish pharmaceutical firm has been hit by a large pricing reform in China. More challenges loom on the horizon in the country, which is the firm’s second-biggest market, as reported by Danish media Finans.
This is because the company’s patent protection on some products are slated to terminate in coming years – starting with Tresiba, Ryzodeg, and Xultophy in 2024. Two years later, the patent for Novo Nordisk’s bestselling drug, GLP-1-based Ozempic, will expire in 2026.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app